• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Repurposing the K < sub > Ca < /sub > 3.1 Blocker Senicapoc for Ischemic Stroke
Transl Stroke Res. 2023 Apr 24. doi: 10.1007/s12975-023-01152-6. Online ahead of print.ABSTRACTSenicapoc, a small molecule inhibitor of the calcium-activated potassium channel KCa3.1, was safe and well-tolerated in clinical trials for sickle cell anemia. We previously reported proof-of-concept data suggesting that both pharmacological inhibition and genetic deletion of KCa3.1 reduces infarction and improves neurologic recovery in rodents by attenuating neuroinflammation. Here we evaluated the potential of repurposing senicapoc for ischemic stroke. In cultured microglia, senicapoc inhibited KCa3.1 currents with an IC50 of 7...
Source: Cell Research - April 24, 2023 Category: Cytology Authors: Ruth D Lee Yi-Je Chen Hai M Nguyen Latika Singh Connor J Dietrich Benjamin R Pyles Yanjun Cui Jonathan R Weinstein Heike Wulff Source Type: research

Predicting risk factors for thromboembolic complications in patients with sickle cell anaemia - lessons learned for prophylaxis
CONCLUSIONS: VTE in patients with SCA has a high impact on morbidity and mortality. PE was the leading presentation of VTE, with CVC insertion, high LDH, bilirubin, CRP and white blood cell counts along with low Hb and HbF constituting other significant risk factors.PMID:34855536 | DOI:10.1177/03000605211055385
Source: Cell Research - December 2, 2021 Category: Cytology Authors: Salam Alkindi Anwaar R Al-Ghadani Samah R Al-Zeheimi Said Y Alkindi Naglaa Fawaz Samir K Ballas Anil V Pathare Source Type: research

Predicting Pain in People With Sickle Cell Disease in the Day Hospital Using the Commercial Wearable Apple Watch: Feasibility Study
CONCLUSIONS: The strong performance of the model in all metrics validates feasibility and the ability to use data collected from a noninvasive device, the Apple Watch, to predict the pain scores during VOCs. It is a novel and feasible approach and presents a low-cost method that could benefit clinicians and individuals with sickle cell disease in the treatment of VOCs.PMID:36917171 | DOI:10.2196/45355
Source: Cell Research - March 14, 2023 Category: Cytology Authors: Rebecca Sofia Stojancic Arvind Subramaniam Caroline Vuong Kumar Utkarsh Nuran Golbasi Olivia Fernandez Nirmish Shah Source Type: research